Multicenter Trial For Patients With Acute Crohn's Disease

Phase 2

Completed

• Conditions: Crohn's Disease

• Registration Number: NCT00035503
• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Brief Summary

The purpose of this study is to see if etiprednol dicloacetate is safe and effective for the treatment of acute Crohn's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01-31
• Study First Submitted: 2002-05-03
• Study First Submitted QC: 2002-05-03
• Study First Posted: 2002-05-06
• Primary Completion: 2004-01-31
• Study Completion: 2004-01-31
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-01
• Last Update Posted: 2021-12-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (11)

Richard MacDermott; 🇺🇸 Albany, New York, United States

University of Chicago Hospital Medical Center; 🇺🇸 Chicago, Illinois, United States

Stuart Weisman; 🇺🇸 Palo Alto, California, United States

Hillary Steinhart; 🇨🇦 Toronto, Ontario, Canada

Mark Lamet; 🇺🇸 Hollywood, Florida, United States

Wayne Schonfeld; 🇺🇸 Hollywood, Florida, United States

Mount Sinai Medical Center; 🇺🇸 Miami Beach, Florida, United States

Gary Wild; 🇨🇦 Montreal, Quebec, Canada

University of Colorado Medical Center; 🇺🇸 Denver, Colorado, United States

Gerald Dryden; 🇺🇸 Louisville, Kentucky, United States

Washington Hospital Center; 🇺🇸 Washington, District of Columbia, United States